De-Escalation of Bone-Targeted Agents for Metastatic Prostate Cancer
Open Access
- 1 February 2016
- journal article
- Published by MDPI AG in Current Oncology
- Vol. 23 (1) , 77-78
Abstract
De-escalation of bone-targeted agents for metastatic prostate cancerKeywords
This publication has 5 references indexed in Scilit:
- Should de-escalation of bone-targeting agents be standard of care for patients with bone metastases from breast cancer? A systematic review and meta-analysisAnnals of Oncology, 2015
- Prevention of symptomatic skeletal events with denosumab administered every 4 weeks versus every 12 weeks: A noninferiority phase III trial (SAKK 96/12, REDUSE).Journal of Clinical Oncology, 2014
- Denosumab Treatment of Prostate Cancer With Bone Metastases and Increased Urine N-Telopeptide Levels After Therapy With Intravenous Bisphosphonates: Results of a Randomized Phase II TrialJournal of Urology, 2009
- Bone markers and their prognostic value in metastatic bone disease: Clinical evidence and future directionsCancer Treatment Reviews, 2008
- Efficacy of Pamidronate in Reducing Skeletal Complications in Patients with Breast Cancer and Lytic Bone MetastasesNew England Journal of Medicine, 1996